BioLife Sciences Inc
BioLife Sciences Inc. develops, licenses, and commercializes products and technologies for the healthcare, beauty, and food and beverage industries. It also offers orthomolecular products. The company is based in Henderson, Nevada.
BioLife Sciences Inc (BLFE) - Total Liabilities
Latest total liabilities as of February 2022: $1.15K USD
Based on the latest financial reports, BioLife Sciences Inc (BLFE) has total liabilities worth $1.15K USD as of February 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioLife Sciences Inc - Total Liabilities Trend (2004–2020)
This chart illustrates how BioLife Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BioLife Sciences Inc Competitors by Total Liabilities
The table below lists competitors of BioLife Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hybrid Energy Holdin
PINK:HYBE
|
USA | $869.49K |
|
Montague International Holding Ltd
PINK:MIHL
|
USA | $5.32 Million |
|
Infusion Brands International Inc
PINK:INBI
|
USA | $49.76 Million |
|
Beard Co
PINK:BRCOQ
|
USA | $11.50 Million |
|
Novation Hldgs Inc.
PINK:NOHO
|
USA | $2.22 Million |
|
EPIC Corp
PINK:EPOR
|
USA | $190.52K |
|
RBC Life Sciences Inc
PINK:RBCL
|
USA | $5.27 Million |
Liability Composition Analysis (2004–2020)
This chart breaks down BioLife Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -10.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioLife Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioLife Sciences Inc (2004–2020)
The table below shows the annual total liabilities of BioLife Sciences Inc from 2004 to 2020.
| Year | Total Liabilities | Change |
|---|---|---|
| 2020-11-30 | $762.30K | +64998.29% |
| 2019-11-30 | $1.17K | -99.47% |
| 2018-11-30 | $222.19K | +13.69% |
| 2017-11-30 | $195.44K | +33.71% |
| 2016-11-30 | $146.16K | +15.10% |
| 2015-11-30 | $126.99K | -96.57% |
| 2007-11-30 | $3.70 Million | +14.85% |
| 2006-11-30 | $3.22 Million | +98.46% |
| 2005-11-30 | $1.62 Million | +9743.68% |
| 2004-11-30 | $16.50K | -- |